← Eichor
Study identifier: NCT06433609 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Condition: Advanced Breast Cancer  ·  Sponsor: Beijing GoBroad Hospital

PhasePhase 2
Planned participants113
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Wei Zhao  ·  +8610-50847588  ·  Zhaow6@gobroadhealthcare.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing GoBroad HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06433609